The crisis investment in loss-making gene therapy company Amsterdam Molecular Therapeutics is a band-aid measure which does not eliminate its negative equity position, but provides it with additional room for manoeuvre.
Gilde Healthcare Partners, the Dutch private equity firm which has Royal Philips as an investor, and Forbion Capital Partners, the former corporate venturing unit of ABN Amro, have helped Euronext-listed healthcare company Amsterdam Molecular Therapeutics raise €2.5m ($3.2m).
Forbion and Gilde were joined by venture firm Advent Venture Partners injecting crisis funds into the company on December 30, after it announced it was in negative equity last month. The three were all previous investors in the gene therapy company, which…
